Physician profile
Tri Ly
NPI 1356923957
$937.95
in general payments reported to CMS, 2019-2025
19 companies · $855 in 2025
The $855 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $19.03 · 2024: $64.11 · 2025: $855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $918.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $166.17 | 2025 | Rexulti |
| Novo Nordisk INC | $150.90 | 2025 | Ozempic, Rybelsus |
| Corcept Therapeutics | $96.90 | 2024-2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.65 | 2025 | Caplyta |
| Intra-Sana Laboratories | $66.35 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Novartis Pharmaceuticals Corporation | $59.29 | 2025 | |
| Lilly USA, LLC | $38.52 | 2024-2025 | Mounjaro, Zepbound |
| Kowa Pharmaceuticals America, INC. | $32.62 | 2025 | Zoryve |
| Exact Sciences Corporation | $32.18 | 2025 | Cologuard Collection Kit |
| Alkermes, INC. | $29.38 | 2025 | Aristada, Lybalvi |
| Abbott Laboratories | $24.38 | 2025 | Freestyle Libre 3 |
| Recordati_rare_diseases_inc. | $19.50 | 2025 | Isturisa |
| Almatica Pharma LLC | $18.78 | 2025 | Loreev Xr |
| Phathom Pharmaceuticals, INC. | $18.47 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $17.41 | 2024 | Arexvy, Trelegy Ellipta |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $16.29 | 2025 | Minimed 780g |
| Tolmar, INC. | $15.27 | 2025 | Jatenzo |
| Astrazeneca Pharmaceuticals Lp | $14.21 | 2025 | Breztri |
| Esperion Therapeutics, INC. | $13.65 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tri Ly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.